Top Markets
#1 CoW Protocol CoW Protocol +84.93%
#2 EXOD EXOD +56.80%
#3 Glidr Glidr +38.25%
#4 Walrus Walrus +36.32%
#5 Humanity Humanity +16.84%
#6 Velvet Velvet +16.00%
#7 Cysic Cysic +15.83%
#8 The Black Bull The Black Bull +14.62%
#9 Tutorial Tutorial +14.59%
#10 Plume Plume +14.14%
Coin of the day
CoW Protocol CoW Protocol
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Quantum Genomics S.A. Quantum Genomics S.A.

Quantum Genomics S.A.

ALQGC
Kedudukan dalam Saham #37063
Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France,... Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France, in 2005, focuses on creating treatments for cardiovascular ailments. Its therapeutic approach utilizes the brain aminopeptidase A inhibition (BAPAI) platform, primarily addressing high blood pressure (hypertension) and heart failure. The company's key asset, firibastat, is currently undergoing a crucial Phase III study as a standalone therapy for hypertension and is also in clinical trials for heart failure. Additionally, Quantum Genomics is progressing QGC011 for hypertension in combination therapy, and further developing QGC006 and QGC606 to target both hypertension and heart failure.
Harga Saham
$0.07600875
Disegerakkan terakhir: 2024-11-20
Modal Pasaran
$2.06M
Perubahan (1 hari)
-0.51%
Perubahan (1 tahun)
0.00%
Negara
FR
Perdagangan Quantum Genomics S.A. (ALQGC)

Kategori

Healthcare
Pendapatan untuk Quantum Genomics S.A. (ALQGC)
Pendapatan pada Dec 2024 TTM: $-9.25M
Menurut laporan kewangan terkini Quantum Genomics S.A., pendapatan semasa syarikat ialah $-9.25M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-3.54M, peningkatan berbanding pendapatan pada tahun 2022 yang berjumlah $-29.48M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Quantum Genomics S.A. dari 2009 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-9.25M 0.00%
2024 $-9.25M 161.14%
2023 $-3.54M -87.98%
2022 $-29.48M 30.61%
2021 $-22.57M 1.34%
2020 $-22.27M 86.84%
2019 $-11.92M -22.86%
2018 $-15.45M 22.30%
2017 $-12.64M 93.73%
2016 $-6.52M 34.15%
2015 $-4.86M 58.10%
2014 $-3.08M 16.82%
2013 $-2.63M 85.17%
2012 $-1.42M 5.32%
2011 $-1.35M -26.18%
2010 $-1.83M -13.18%
2009 $-2.11M 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -57,102.94%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -21,179.60%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -32,581.13%
BE